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Immunologic Status of Uremic Patients 
Gerald A. LoGrippo, M.D.,* C. E. Rupe, M.D.,** 
Hajime Hayashi, Ph.D.,* and Dean LeSher, Ph.D., M.D.** 
The immunologic status of 25 uremic patients was studied with a battery of tests 
evaluating the humoral and cytological aspects of immunity. The individual's 
humoral immune status was evaluated as follows: quantitation of the three major 
serum immunoglobulins (IgG, IgA and IgM) expressed in mg/100 ml of serum 
and compared to established normal clinical standards (±2 SD/mean); qualitation 
of IgG and IgM evaluated by specific virus antibody titers and antitoxin values 
associated with IgG and by isoagglutinin tilers of the ABO blood groups associated 
with IgM. Immunoglobulin status is grouped into hyper- and hypo-immunogiohu-
lin variations from normal and correlated with serum complement values 
(BetUic fi.i and hemolytic activity). The cytological status in the evaluation consists 
of assaying the individual's ability to produce interferon by the Sendai-Sindbis 
virus system in peripheral blood leukocytes. Results of the study emphasize the 
need for individual evaluation of uremic patients to enable more effective im-
muno-depressive therapy before and after renal transplantation. 
Some investigators have suggested 
that long-standing uremia depresses 
the lymphoreticular system with result-
ing immuno-suppression.-^ Under-
standing the nature and degree of such 
immuno-depression may be critically 
important in the control of renal allo-
graft rejection reactions. In order to 
differentiate between graft rejections 
and super infections, there should be 
precise evaluation of the patient's im-
munologic status before renal allo-
graft. = 
Our approach to what is termed 
"immunologic evaluation of the indi-
vidual" is an attempt to measure the 
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biologic status of the lymphoreticular 
system quantitatively and qualitatively. 
The quantity of the three major serum 
immunoglobulins is determined by 
methods, clinical standards and criteria 
reported elsewhere.i'^  *" In this paper 
we report the degrees and variations in 
immunologic factors found in 25 ure-
mic patients. The findings offer some 
interesting aspects to organ transplan-
tation problems and suggest a different 
view in the management of the patient, 
both before and after organ transplan-
tation. 
Patients and Methods 
Twenty-five patients in the acute and 
chronic stages of uremia were evalu-
ated. Although multiple evaluations 
were made, the tables have been simpli-
fied to show only one evaluation for 
each patient. The parameters employed 
in evaluating individual immunologic 
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status are shown in Figure 1. The 
humoral immune status is reflected in 
the quantitation and qualitation of the 
major immune factors in the serum. 
The cytological immune status is par-
tially reflected in the interferon re-
sponse in peripheral blood leukocytes. 
In this report quality of the IgG class 
is indicated by the antibody responses 
to 12 enteric viruses,four upper res-
piratory viruses and two antitoxins. 
IgM is qualitated by the ABO blood 
group isoagglutinin titers in sertim 
when applicable. IgA cannot be satis-
factorily qualitated at this time. 
Quantitative Determination: 
Serum immunoglobulins (IgG, IgA 
and IgM) were determined by a micro-
double diffusion in agar technic de-
veloped and standardized in this labo-
ratory." Normal adult serum immuno-
globulin levels have been found to 
range (mean ± 2 standard deviations) as 
follows: 600-1400 mg/100 ml for IgG; 
30-135 mg/100 ml for IgA and 40-
120 mg/100 ml for IgM. Serum globu-
lin (Betaic/iA) complement was quanti-
tated by the same micro-double diffu-
sion technic as employed for the Igs. 
Normal serum level by this procedure 
was found to be 100-200 mg/100 ml 
serum ( ± 2 SD from mean value). 
Serum Neutralizing Antibody Titers: 
Virus neutralizing antibody (VNAT) 
titers were determined for the enteric 
viruses. These were carried out in plas-
tic plates rather than the usual tissue 
culture tube method. ^  Twelve strains 
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of entero viruses are routinely used to 
evaluate the antibody quality associ-
ated with IgG. These include: polio-
myelitis prototypes 1, 2 and 3; Cox-
sackie A9, B-1, B-2, B-3, B-4, B-5 and 
Echo 6, 9 and 14. Enteric virus anti-
body titers generally are consistently 
present throughout the year and are 
more reliable measurement for indi-
vidual evaluation studies. In addition, 
the enteric viruses selected for anti-
body evaluation in individual patients 
are those vhus strains which are con-
sistently present in blood bank plasma 
pools throughout the year.^  
Hemagglutination Titration: 
The hemagglutination procedures 
used for diptheria and tetanus antitox-
ins associated with IgG were essentially 
the method of Levine et al,* but 
adapted to microtiter technics in plas-
tic micro plates.^  Serum dilution titers 
were converted to antitoxin units per 
ml of sera by paraUel tests conducted 
with known standard antitoxins. Diph-
theria and tetanus antitoxin values 
50.04 units/ml are considered ade-
quate serum residual levels for a com-
petent immunoglobulin-G system. Les-
ser quantities are not detectable and 
warrant challenge with toxoid doses for 
anamnistic responses. Qualitation of 
IgM was determined by isoagglutinin 
titers to the ABO blood groups by 
standard blood bank procedures. 
In Vitro Interjeron Response oj 
Peripheral Blood Leukocytes: 
The individual's leukocyte immune 
status in regard to viruses (ie his abil-
ity to respond with interferon produc-
tion) was determined in vitro. In a com-
parative study between humoral im-
mune status and interferon response in 
health and disease we found no inter-
feron titer of 1:8 or less among healthy 
individuals fulfilling our criteria.^ 
Therefore, titers of 1:32 or greater are 
considered "good responses" in this 
test system; a titer of 1:16 is a "low 
borderline response" and a titer of 1:8 
or less, a "poor response." 
Serum Complement 
Complement activity was deter-
mined at the 50% hemolytic end pomt 
as described by Heidelberger.io.n We 
modified this procedure slighdy in the 
dilutions used and determined the 
hemolytic activity by optical density at 
545 millimicrons in a Coleman Jr. 
Spectrophotometer. Complement activ-
ity was calculated and expressed as 
50% hemolytic units per ml of serum. 
The mean normal value for this pro-
cedure is 175 ( ± 1 SD) with a range of 
150 to 200 units/ml. However, for 
practical reasons we consider 2 SD as 
meaningful and the values ( ± 2 SD), 
which range from 125 to 225 units/ml, 
as more significant. See Tables I-IV. 
Results 
The data on the 25 uremic patients 
have been grouped into five tables (I to 
V) according to immunoglobulin levels. 
Because the immune status for indi-
viduals with serial studies did not 
vary with time and repeated evalu-
ations, only one evaluation is given 
for each patient. Arrows indicate 
those values above or below two 
standard deviations from the mean 
as established in this laboratory.® The 
remaining three parameters (antibody 
response, leukocyte interferon yield, 
and complement factors) are compared 
with each of the immunoglobulin find-
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Table I 
IMMUNOLOGIC STATUS OF UREMIC PATIENTS 
IgG-Group 
Pt. 
IMMUNOGLOBULINS: ANTIBODY RESPONSE: VIS COMPLEMENT 
(Ig-Quantity)' (IgG-Quality) (WBC) 50%H 
U/ml 
|3lc/,A 
mq% 
IgG IgA 1 IgM 12 Vir's 2-Tox's 1:32 150-200 100-200 
U-8 420 i 1 19*1 18t 7/10 1/2 64 91 167 
U-10 3091 1 61 1 28^ 6/10 0/2 NT 132 101 
U-11 304* 99 ' 106 4/10 2/2 NT 137 132 
U-17 370 i 72 1384 4/10 2/2 32 93 155 
U-21 370 i ' 24t' 61 7/10 2/2 32 76 29 
U-22 404f 24* 14t 3/10 1 1/2 64 153 126 
U-7 17771 217*1 104 5/10 2/2 NT 187 195 
U-24 1564* 1 98 16U 7/10 2/2 8 111 117 
•Ig Values (2SD) 
NT = Not Tested 
" > 1:16 titer > 0.04 u/ml 
ings. In table I , the eight uremic pa-
tients who showed variations from nor-
mal in IgG are grouped together. Six 
of the eight showed low IgG quantity, 
and two showed greater than two stan-
dard deviations above the normal 
serum levels for IgG. Although IgG 
values are low in quantity in six of these 
patients, the quality is good. This is re-
flected in the high serum antibody 
titers found for 12 enteric viruses and 
two toxins tested; the numerators rep-
resent the number of viruses having 
antibody titers equivalent to or greater 
than 1:16 dilution. In antitoxin values, 
the numerator indicates serum levels 
50.04 units/ml, the minimal detectable 
amount. In the third colimin labeled 
VIS (Virus Inhibitory Substance) a 
level above 1:32 dilution is found in 
all but one of the patients tested. In the 
last column, the serum complement 
values show a significant decrease in 
hemolytic activity, and in one instance 
a decrease in the quantitation of 
B e t a k e O f the two hyper-immuno-
globulin-G patients, one shows low 
hemolytic activity associated with nor-
mal quantity of Betake/IA component 
while the other has normal complement 
values. 
Table I I includes those patients who 
had elevated IgA levels. Eight of the 
25 patients with uremia fell into this 
group, showing elevations of IgA above 
two standard deviations from normal 
mean value. Since the biologic activity 
of IgA cannot be adequately assayed 
at this time, its quality cannot be de-
termined. Antibody responses associ-
ated with IgG were good and interferon 
responses were found to be low in two 
of the five patients tested. Decreased 
complement values were found in six 
of the eight patients'. We are not cer-
tain whether the low complement 
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Table I I 
IMMUNOLOGIC STATUS OF UREMIC PATIENTS 
IgA-Group ( t ) 
IMMUNOGLOBULINS: ANTIBODY RESPONSE VIS COMPLEMENT 
(Ig-Quantity)' (IgG-Quality) (WBC) 50%H I 3 le/iA 
Pt. U/ml 1 mg% 
IgG 1 IgA 1 IgM *« 
12 Vir's 
2-Tox's 1:32 150-200 1 100-200 
U-1 1080 145* 80 4/11 2/2 NT 128 95 
U-2 1392 1651 70 7/11 2/2 32 100 150 
U-7 177711 217 f l 104 5/10 2/2 NT 187 1 195 
U-9 948 168f| 94 10/10 2/2 16 0 \ 138 
U-13 856 1 23Ui 30* 4/10 NT NT 119 1 86 
U-19 949 182f| 53 6/10 2/2 28 90 95 
U-23 1330 1 150^ 115 7/10 1/2 4 221 , 177 
U-25 1023 ' 254*' 98 10/10 2/2 32 114 ' 68 
• Ig Values (2SD) 
NT = Not Tested 
" > 1:16 titer > 0.04 u/ml 
Table I I I 
IMMUNOLOGIC STATUS OF UREMIC PATIENTS 
IgA-Group ( I ) 
IMMUNOCy-OBULINS: ANTIBODY RESPONSE: VIS COMPLEMENT 
(Ig-Quantity)* (IgG-Quality) (WBC) 50%H ppc/w 
Pt. U/ml mg% 
IgG 1 IgA IgM 
«« 1 • • * 
12 Vir's 1 2-Tox's 1:32 150-200,100-200 
U-5 902 1 251 28V 5/12 1/2 64 256 I 339 
U-8 4201 1 19* 1 18* 7/10 1 1/2 64 91 1 167 
U-18 1226 1 29* 46 4/9 1/2 32 93 83 
U-21 3701 1 24* 1 61 7/10 1 2/2 32 76 > 29 
U-22 404t 24* 1 14* 3/10 1 1/2 64 153 1 126 
*lg Values (2SD) •* > 1:16 titer > 0.04 u/ml 
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Table IV 
IMMUNOLOGIC STATUS OF UREMIC PATIENTS 
IgM-Group 
IMMUNOGLOBULINS: ANTIBODY RESPONSE: VIS COMPLEMENT 
(Ig-Quantity)* (IgG-Quality) (WBC) 50%H ' 
U'ml I mg% 
Pt. IgG IgA IgM 12 Vir's 2-Tox's 1:32 150-200^  100-200 
u-8 420 + 19+ 18 + 7/10 1 1/2 64 91 1 167 
U-5 902 25* 28+ 5/12 1 2/2 64 256 J 339 
U-6 805 109 1 17+ 4/12 1 1/2 256 140 108 
U-13 856 231| 1 30+ 4/10 2/2 16 119 1 86 
U-22 404 i 24+ 1 14+ 3/6 1 1/2 64 153 126 
U-10 309 + 61 28+ 6/10 ' 0/2 
1 
NT 132 101 
U-4 942 85 151 + 5/12 I 0/2 128 217 167 
U-17 370 + 72 ' 138+ 4/10 ' 2/2 32 93 155 
U-24 1564 + 98 161+ 7/10 1 2/2 8 111 117 
* Ig Values (2SD) 1:16 titer > 0.04 u/ml 
NT = Not Tested 
values indicate the individual's inabil-
ity to synthesize this component, or 
whether increased utilization is taking 
place from antigen-antibody reactions. 
Table I I I shows five uremic patients 
with IgA values below normal. It will 
be noted that two of these (patient U-8 
and U-22) are below normal in all 
three immunoglobulin classes. In spite 
of this the antibody responses are con-
sidered good in terms of specific neu-
tralizing antibody titers associated with 
IgG. Leukocyte interferon responses 
are within normal range of activity, and 
complement factors are well below 
normal values in three of the five pa-
tients. 
Table IV gives the data on patients 
who show alterations from normal in 
the IgM class; six show low values and 
three show IgM values above two stan-
dard deviations from the mean. The 
viral antibody titers for all nine patients 
in this group were good, even though 
four of the nine patients had below 
standard serum level values for IgG. 
Al l patients with IgM values below 
normal who were tested for leukocyte 
interferon showed normal responses, 
whereas one of three patients with 
IgM values above normal showed 
"poor" interferon response in periph-
eral blood leukocytes. Complement 
values varied in this group without a 
consistent trend. The IgM group was 
similar to the IgG and IgA groups in 
regard to variations from normal and 
lack of correlation between comple-
ment factors and interferon responses. 
Table V shows that six of the 25 pa-
tients had normal values for all three 
immunoglobulin classes. In this group 
all six had good virus serum antibody 
levels, all but one showed normal titers 
against bacterial toxins, all had normal 
interferon responses, and only one pa-
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Table V 
IMMUNOLOGIC STATUS OF UREMIC PATIENTS 
Normals 
IMMUNOGLOBULINS: ANTIBODY RESPONSE: VIS COMPLEMENT 
(Ig-Quantity)* (IgG-Quality) (WBC) 50%H 1 P.c/,A 
U/ml ' mq% 
IgG , IgA 1 IgM 12 Vir's 2-Tox's 1:32 150-2001100-200 
U-3 565 ^1 42 1 47 6/12 1/2 32 69 1 131 
U-12 645 1 94 ; 59 10/10 0/2 NT 195 ] 104 
U-14 1179 1 86 1 87 3/10 2/2 128 149 1 93 
U-15 796 ] 126 ; 54 8/10 2/2 >128 182 1 101 
U-16 770 1 131 1 111 4/10 2/2 64 145 1 119 
U-20 978 ' 56 1 98 8/10 2/2 32 120 ' 132 
*lg Values (2SD) **> 1:16 titer 
NT = Not Tested 
tient showed low complement activity. 
The isoagglutinin titers associated 
with the IgM of all patients studied 
with ABO blood group types were 
found to be greater than 1:16 in serum 
dilution. To simplify the data these re-
sults were not included in the tables. 
Discussion 
The degrees and variations in the 
immunologic status of 25 uremic pa-
tients were considerable. Although both 
serum immunoglobulin deficiencies and 
excesses were found, immunoglobulin 
dyscrasias, ie, normal Ig values without 
biologic activity,^ were not detected 
among the 25 patients studied. The 
quality of specific antibody responses 
associated with IgG and IgM are ade-
quate in uremic patients as reflected in 
the virus neutralizing antibody titers, 
antitoxin values and isoagglutinin titers 
to the ABO Blood Groups. Suitable 
qualitation associated with IgA is not 
available at this time. In regard to the 
cellular defense system, leukocyte in-
terferon responses were found to be 
*** > 0.04 u/ml 
"poor" in two patients and "low bor-
derline" in two others. Al l of the re-
maining patients tested showed good 
leukocyte interferon responses. Our in-
terpretation of the poor and low re-
sponses suggests a leukocyte ineffi-
ciency in the mass population of the 
peripheral blood leukocytes or an in-
ability of the leukocytes to respond 
with interferon production by some 
physiologic block. What this means to 
the host's defense mechanism warrants 
further investigation. 
The measurements on serum com-
plement quantity (Betaic/iA) and as-
sociated hemolytic activity vary from 
normal status to persistently low values 
in some patients. No consistent corre-
lation could be found between serum 
complement values and the other im-
mune factors studied. 
The immunologic variations in 25 
uremic patients indicate that few gen-
eralizations can be made and that indi-
vidual appraisal of each patient's im-
mune status may be required. In addi-
tion, more adequate clinical interpre-
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tation and qualification may be neces-
sary if immmuno-depressive therapy is 
to be applied more rationally before 
and after kidney transplantation in 
uremic patients. Individuals with im-
munoglobulin excesses may necessitate 
and tolerate larger doses of immuno-
depressive drug therapy than individ-
uals with immunoglobulin deficiencies. 
Moreover, patients with immunoglobu-
lin deficiences may warrant passive im-
munity therapy (similar to agammaglo-
bulinemic patients) prior to surgery in 
the form of commercial gammaglobu-
lin, hepatitis-free pooled plasma^ '^^ * or 
both. Current practice in the manage-
ment of homotransplantation tends to 
follow a pattern of dosage of immuno-
suppressive agents varying only with 
time and evidence of graft rejection. 
The results reported here suggest that 
therapy should be based on the indi-
vidual's immune status. Obviously 
"rules of thumb" are to be avoided in 
the prophylaxis of transplant rejection 
and we suggest the same considerations 
for any individual being evaluated for 
any organ transplantation. 
The changes in immunologic status 
following nephrectomy and kidney 
transplantation have been studied in 
more detail and are planned for a sub-
sequent publication. 
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